Form 8-K - Current report:
SEC Accession No. 0000950170-25-078933
Filing Date
2025-05-29
Accepted
2025-05-29 16:05:25
Documents
11
Period of Report
2025-05-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K igms-20250523.htm   iXBRL 8-K 53390
2 EX-10.1 igms-ex10_1.htm EX-10.1 60337
  Complete submission text file 0000950170-25-078933.txt   236896

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT igms-20250523.xsd EX-101.SCH 32364
13 EXTRACTED XBRL INSTANCE DOCUMENT igms-20250523_htm.xml XML 4531
Mailing Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043
Business Address 325 E MIDDLEFIELD ROAD MOUNTAIN VIEW CA 94043 650-965-7873
IGM Biosciences, Inc. (Filer) CIK: 0001496323 (see all company filings)

EIN.: 770349194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39045 | Film No.: 251003279
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)